SCHEMBL5540924

SCHEMBL5540924

Cc1cccc(N2CCC(O[C]=O)CC2)c1

nearest known ligand 0.51

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NOTUM Q6P988 1/20 0.51
GPR119 Q8TDV5 1/20 0.50
ADRB1 P08588 1/20 0.50
ACACB O00763 2/20 0.47
KCNH2 Q12809 2/20 0.46
FFAR4 Q5NUL3 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MAPT P10636 2/20 0.43
RAB9A P51151 1/20 0.43
NPY5R Q15761 1/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
C1S P09871 1/20 0.40
CA12 O43570 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
CA9 Q16790 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12093607 0.81 ADRB1 (0.56) NOTUMGPR119ADRB1ACACBKCNH2
SCHEMBL5540468 0.81 MAPT (0.47) GPR119ADRB1ALDH1A1MAPTRAB9A
SCHEMBL5536217 0.81 MBTD1 (0.47) NOTUMGPR119ADRB1ACACBFFAR4
SCHEMBL5536945 0.80 L3MBTL3 (0.43) ACACBKCNH2L3MBTL1
SCHEMBL5540929 0.79 NOTUM (0.51) NOTUMGPR119ADRB1ACACBKCNH2
SCHEMBL5539228 0.79 NOTUM (0.54) NOTUMACACBALDH1A1MAPTL3MBTL1
SCHEMBL5541989 0.77 NOTUM (0.43) NOTUMACACBALDH1A1MAPTL3MBTL1
SCHEMBL5538569 0.77 MAPT (0.46) ALDH1A1MAPT
SCHEMBL8054516 0.76 ADRB1 (0.61) NOTUMGPR119ADRB1KCNH2FFAR4
SCHEMBL25015826 0.76 NOTUM (0.57) NOTUMGPR119ADRB1ACACBKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 NOTUM 3827/4885GPR119 658/4885ADRB1 150/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.